<DOC>
	<DOCNO>NCT02369471</DOCNO>
	<brief_summary>To evaluate pharmacokinetics , safety tolerability GWP42006 compare placebo , presence antiepileptic drug ( AEDs ) .</brief_summary>
	<brief_title>A Study GWP42006 People With Focal Seizures - Part A</brief_title>
	<detailed_description>This double blind , randomize , placebo control , two-part study . Part A described record . Subjects satisfy inclusion none exclusion criterion begin 14-day baseline observation period follow 14-day treatment period . Subjects require attend six study visit . A follow-up phone call take place four week last dose . Part A enroll three group 10 subject : - Group 1 - subject inducer AEDs ( inhibitor AEDs ) - Group 2 - subject inhibitor AEDs ( inducer AEDs ) - Group 3 - subject AEDs neither inducer inhibitor . In three group subject randomized receive , 4:1 ratio , GWP42006 400 mg twice daily match placebo . Pharmacokinetic ( PK ) profile GWP42006 metabolite collect first last day treatment . Samples also collect 24h 72h last day treatment . Subjects require record daily diary information seizure , investigational medicinal product ( IMP ) concomitant AED administration .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<criteria>For inclusion Part A study patient must fulfil ALL follow criterion : Male female age 18 65 year , inclusive . Welldocumented history focal epilepsy , focal seizure primary seizure type , compatible electroencephalogram clinical history . Documented computerized tomography / magnetic resonance imaging show progressive neurologic abnormality . Has focal seizure despite prior treatment least two AEDs ( whether monotherapies combination ) . Currently treat one three AEDs follow : Group 1 subject inducer AEDs ( inhibitor AEDs ) Group 2 subject inhibitor AEDs ( inducer AEDs ) Group 3 subject AEDs neither inducer inhibitor . All medication intervention epilepsy ( include ketogenic diet neurostimulation device epilepsy ) must stable two week prior screen patient willing maintain stable regimen throughout study . Subject willing keep factor expect affect seizure stable ( level alcohol consumption smoking ) . The patient may enter Part A study ANY follow apply : Time onset epilepsy treatment less two year prior enrolment . Episode ( ) status epilepticus one year prior screen . History pseudoseizures . Subject clinically significant unstable medical condition epilepsy . Subject illness four week prior screen randomization , epilepsy , opinion investigator would affect seizure frequency . Subject significantly impair hepatic function Visit 1 . Active suicidal plan/intent past six month , history suicide attempt last two year , one lifetime suicide attempt . Subject currently use past use recreational medicinal cannabis , cannabinoid base medication within three month prior screen unwilling abstain duration study . Subject take St John 's Wort last two week and/or unwilling abstain throughout study . Subject consume grapefruit grapefruit juice three day prior randomization and/or unwilling abstain three day prior Visits A2 A4 . Any known suspected hypersensitivity cannabinoids , sesame oil excipients IMP ( ) . Subjects receive IMP within 12 week prior screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Cannabidivarin</keyword>
	<keyword>CBDV</keyword>
	<keyword>GWP42006</keyword>
</DOC>